secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protara Therapeutics, Inc. (TARA)
CIK:        0001359931
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0001213900-22-001222
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protara Therapeutics appoints Jathin Bandari as Chief Medical Officer
---------------------------------------------------------------------

- Dr. Bandari, previously Interim CMO, appointed permanent CMO effective Jan 10, 2022.
- Annual base salary of $415,000, discretionary bonus target 40% of base.
- Granted stock option for 81,000 shares and RSU for 13,500 shares, subject to board approval.
- Severance: 9 months salary plus target bonus and healthcare if terminated without cause or for good reason.
- In change of control termination, 100% acceleration of unvested equity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022001222/0001213900-22-001222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1359931/000121390022001222/ea153715-8k_protarathera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-001222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer